Aclidinium bromide/formoterol fumarate fixed-dose combination - A suitable dual bronchodilation therapy for COPD
Abstract
The search for the ideal combination of long-acting beta-agonists (LABAs) and muscarinic agonists (LAMAs) has been the subject of intensive research in recent years. COPD morbidity and mortality continue to increase, being contributed to by ageing of the population.
The article is concerned with the properties and advantages of aclidinium bromide/formoterol fumarate fixed-dose combination delivered in a single inhaler, as compared to monotherapy with the two agents or separate administration of both in two inhalers. One of the benefits of the fixeddose combination is twice-daily administration contributing to better control of symptoms, especially morning and early diurnal ones, which are of crucial importance to the quality of life of COPD patients.